UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K, including the press release attached
to this Form 6-K as Exhibit 99.1, is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8
(File No. 333-229163, 333-248479,
333-263842, 333-271320
and 333-279791) and Form F-3
(File No. 333-238731,
333-292640 and 333-297347),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
On September 3, 2026, CollPlant Biotechnologies
Ltd. (the “Company”) completed its previously announced acquisition of LightSolver Ltd. (“LightSolver”) pursuant
to the Share Purchase Agreement, dated August 29, 2026, by and among the Company, LightSolver and the shareholders of LightSolver.
On September 3, 2026, the Company issued a press release entitled “Collplant Completes Acquisition of Lightsolver, Entering the
Photonic Computing Sector.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following
exhibits:
| 99.1 |
|
Press Release, dated September 3, 2026. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
COLLPLANT BIOTECHNOLOGIES LTD. |
| |
|
|
| Date: September 3, 2026 |
By: |
/s/ Eran Rotem |
| |
|
Name: |
Eran Rotem |
| |
|
Title: |
Deputy CEO and Chief Financial Officer |
Exhibit 99.1
COLLPLANT COMPLETES
ACQUISITION OF LIGHTSOLVER, ENTERING THE
PHOTONIC COMPUTING SECTOR
| ● | Technological
Edge - LightSolver advances the development of the world’s first Laser Processing
Unit (LPU) – an energy-efficient, pure photonic computing platform |
| ● | Accelerated
Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization
and expand engagements with strategic partners. |
REHOVOT, Israel, September 3, 2026 – CollPlant
Biotechnologies Ltd. (Nasdaq: CLGN) today announced the successful closing of its previously announced acquisition of LightSolver Ltd.
(“LightSolver”), an Israeli deep-tech company pioneering a fundamentally new computing paradigm based on lasers.
With the closing of this transaction, CollPlant
officially enters the high-performance computing (HPC) and photonics sectors. LightSolver’s Laser Processing Unit (LPU) is designed
to accelerate some of the most computationally demanding workloads, while the transaction provides the resources to accelerate its commercialization,
expand strategic partnerships, and advance LightSolver’s long-term technology roadmap.
Executive Commentary
“We are pleased to complete this transaction
with LightSolver, marking CollPlant’s entry into the photonics computing sector,” said Yehiel Tal, Chairperson and Chief Executive
Officer of CollPlant. “This exciting new field of activity will run alongside our continued and active operations in regenerative
medicine.”
Dr. Ruti Ben Shlomi, Founder and Chief Executive
Officer of LightSolver, commented, “Today marks an important milestone for our technology. We believe this next chapter will help
us accelerate our technology roadmap and pursue commercial opportunities for our LPU platform globally. We remain focused on redefining
the boundaries of computing speed and energy efficiency for our partners and the industry globally.”
Transaction Overview
As detailed in the definitive agreement
announcement on August 31, 2026, the acquisition was completed utilizing an equity-centric consideration structure. At closing, CollPlant
among others issued upfront ordinary shares, pre-funded warrants and an investment of $5 million in LightSolver. Additional milestone-based
warrants will become exercisable upon LightSolver’s achievement of specified technological and commercial objectives.
Additional details about the transaction
are available in the Company’s Report on Form 6-K, which was filed with the Securities and Exchange Commission on August 31, 2026.
About LightSolver
LightSolver is an Israeli deep-tech company pioneering a new generation
of high-performance computing based on the physics of light. Founded in 2020 by Weizmann Institute physicists Dr. Ruti Ben Shlomi and
Dr. Chene Tradonsky, LightSolver is the developer of the Laser Processing Unit™ (LPU™), a proprietary all-optical
computing architecture that uses coupled lasers to perform computation.
The LPU™ is designed to accelerate computationally intensive
workloads including scientific and engineering simulation, partial differential equations, large-scale linear systems and optimization,
with applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.
LightSolver is advancing its technology toward commercial deployment
in collaboration with leading global organizations.
For more information about LightSolver, visit lightsolver.com.
About CollPlant
CollPlant is a pioneering technology company operating at the forefront
of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant
has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser
Processing Unit™ (LPU™). This bold diversification positions the Company to address some of the world’s most computationally
intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations.
In the healthcare sector, CollPlant is ushering in a new era of medical
solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company’s products are
based on its recombinant human collagen produced with CollPlant’s proprietary plant-based genetic engineering technology, addressing
indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
For more information about CollPlant, visit collplant.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding
the acquisition of LightSolver by CollPlant; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction;
LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver’s Laser
Processing Unit™ (LPU™) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver
and the combined business. Forward-looking statements can be identified by words such as “anticipate,” “believe,”
“expect,” “intend,” “plan,” “may,” “should,” “could,” “might,”
“seek,” “target,” “will,” “project,” “continue” and similar expressions or
the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s
experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside
of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated
in forward- looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to
closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of
the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver’s
business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties
regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s
products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition
and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance
with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described
in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and
subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by applicable law.
Contact
Information:
CollPlant
Eran
Rotem, Deputy CEO & CFO
Email:
Eran@collplant.com
LightSolver
Ltd.
Dr.
Ruti Ben Shlomi, Founder & CEO
Email:
Ruti@lightsolver.com